Happy Holidays from the Canadian Fabry Association!
Information on the Webinar hosted by Julia Alton
Exciting news for the CFA Community – Replagal has been approved by Health Canada as of February 2017 and all patients have been transitioned from the REP-081 study at this point. Replagal is a long-term Enzyme Replacement Therapy (ERT), the infusion will be given every 2 weeks, treatment time being approximately 4o minutes. It is […]
Excited to share Health Canada’s approval of the oral- precision medicine Galafold! We look forward to this differentiated treatment option for Canadian patients with amenable mutations. Please see the press release for further information.
Ontario Patients – Please join us for our very first Patient Empowerment Pilot Project Workshop.
The CFA is honoured and proud to share this Rare Disease Hero Video featuring Kaye LeMoine….
In the 16-week clinical trials expected to start later this year — if the research method is given the nod by the QE II’s ethics committee — the researchers led by West and Khan will measure the effects of the drug apabetalone on 44 patients suffering with Fabry disease.
The Board is responsible for the highest level of decision-making and communicates the organization’s vision to all members and the community.
The Annual WORLDSymposium is often cited as the most important scientific meeting on lysosomal molecular biology, disorders and treatment.
The Canadian Organization for Rare Disorders (CORD) is hosting a Rare Disease Day 2017 conference taking place on March 30-31, 2017.